↓ Skip to main content

Dose-Response Association of CD8+ Tumor-Infiltrating Lymphocytes and Survival Time in High-Grade Serous Ovarian Cancer

Overview of attention for article published in JAMA Oncology, December 2017
Altmetric Badge

About this Attention Score

  • In the top 5% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (97th percentile)
  • Good Attention Score compared to outputs of the same age and source (75th percentile)

Mentioned by

news
2 news outlets
blogs
1 blog
twitter
105 X users
facebook
2 Facebook pages
googleplus
1 Google+ user

Citations

dimensions_citation
279 Dimensions

Readers on

mendeley
172 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Dose-Response Association of CD8+ Tumor-Infiltrating Lymphocytes and Survival Time in High-Grade Serous Ovarian Cancer
Published in
JAMA Oncology, December 2017
DOI 10.1001/jamaoncol.2017.3290
Pubmed ID
Authors

Ellen L. Goode, Matthew S. Block, Kimberly R. Kalli, Robert A. Vierkant, Wenqian Chen, Zachary C. Fogarty, Aleksandra Gentry-Maharaj, Aleksandra Tołoczko, Alexander Hein, Aliecia L. Bouligny, Allan Jensen, Ana Osorio, Andreas D. Hartkopf, Andy Ryan, Anita Chudecka-Głaz, Anthony M. Magliocco, Arndt Hartmann, Audrey Y Jung, Bo Gao, Brenda Y. Hernandez, Brooke L. Fridley, Bryan M. McCauley, Catherine J. Kennedy, Chen Wang, Chloe Karpinskyj, Christiani B. de Sousa, Daniel G. Tiezzi, David L. Wachter, Esther Herpel, Florin Andrei Taran, Francesmary Modugno, Gregg Nelson, Jan Lubiński, Janusz Menkiszak, Jennifer Alsop, Jenny Lester, Jesús García-Donas, Jill Nation, Jillian Hung, José Palacios, Joseph H. Rothstein, Joseph L. Kelley, Jurandyr M. de Andrade, Luis Robles-Díaz, Maria P. Intermaggio, Martin Widschwendter, Matthias W. Beckmann, Matthias Ruebner, Mercedes Jimenez-Linan, Naveena Singh, Oleg Oszurek, Paul R. Harnett, Peter F. Rambau, Peter Sinn, Philipp Wagner, Prafull Ghatage, Raghwa Sharma, Robert P. Edwards, Roberta B. Ness, Sandra Orsulic, Sara Y. Brucker, Sharon E. Johnatty, Teri A. Longacre, Ursula Eilber, Valerie McGuire, Weiva Sieh, Yanina Natanzon, Zheng Li, Alice S. Whittemore, Anna deFazio, Annette Staebler, Beth Y. Karlan, Blake Gilks, David D. Bowtell, Estrid Høgdall, Francisco J. Candido dos Reis, Helen Steed, Ian G. Campbell, Jacek Gronwald, Javier Benítez, Jennifer M. Koziak, Jenny Chang-Claude, Kirsten B. Moysich, Linda E. Kelemen, Linda S. Cook, Marc T. Goodman, María José García, Peter A. Fasching, Stefan Kommoss, Suha Deen, Susanne K. Kjaer, Usha Menon, James D. Brenton, Paul D. P. Pharoah, Georgia Chenevix-Trench, David G. Huntsman, Stacey J. Winham, Martin Köbel, Susan J. Ramus

Abstract

Cytotoxic CD8+ tumor-infiltrating lymphocytes (TILs) participate in immune control of epithelial ovarian cancer; however, little is known about prognostic patterns of CD8+ TILs by histotype and in relation to other clinical factors. To define the prognostic role of CD8+ TILs in epithelial ovarian cancer. This was a multicenter observational, prospective survival cohort study of the Ovarian Tumor Tissue Analysis Consortium. More than 5500 patients, including 3196 with high-grade serous ovarian carcinomas (HGSOCs), were followed prospectively for over 24 650 person-years. Following immunohistochemical analysis, CD8+ TILs were identified within the epithelial components of tumor islets. Patients were grouped based on the estimated number of CD8+ TILs per high-powered field: negative (none), low (1-2), moderate (3-19), and high (≥20). CD8+ TILs in a subset of patients were also assessed in a quantitative, uncategorized manner, and the functional form of associations with survival was assessed using penalized B-splines. Overall survival time. The final sample included 5577 women; mean age at diagnosis was 58.4 years (median, 58.2 years). Among the 5 major invasive histotypes, HGSOCs showed the most infiltration. CD8+ TILs in HGSOCs were significantly associated with longer overall survival; median survival was 2.8 years for patients with no CD8+ TILs and 3.0 years, 3.8 years, and 5.1 years for patients with low, moderate, or high levels of CD8+ TILs, respectively (P value for trend = 4.2 × 10-16). A survival benefit was also observed among women with endometrioid and mucinous carcinomas, but not for those with the other histotypes. Among HGSOCs, CD8+ TILs were favorable regardless of extent of residual disease following cytoreduction, known standard treatment, and germline BRCA1 pathogenic mutation, but were not prognostic for BRCA2 mutation carriers. Evaluation of uncategorized CD8+ TIL counts showed a near-log-linear functional form. This study demonstrates the histotype-specific nature of immune infiltration and provides definitive evidence for a dose-response relationship between CD8+ TILs and HGSOC survival. That the extent of infiltration is prognostic, not merely its presence or absence, suggests that understanding factors that drive infiltration will be the key to unraveling outcome heterogeneity in this cancer.

X Demographics

X Demographics

The data shown below were collected from the profiles of 105 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 172 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 172 100%

Demographic breakdown

Readers by professional status Count As %
Researcher 23 13%
Student > Ph. D. Student 21 12%
Student > Bachelor 14 8%
Student > Master 14 8%
Other 10 6%
Other 35 20%
Unknown 55 32%
Readers by discipline Count As %
Medicine and Dentistry 40 23%
Biochemistry, Genetics and Molecular Biology 28 16%
Agricultural and Biological Sciences 13 8%
Immunology and Microbiology 6 3%
Engineering 3 2%
Other 14 8%
Unknown 68 40%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 83. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 09 July 2019.
All research outputs
#512,133
of 25,413,176 outputs
Outputs from JAMA Oncology
#841
of 3,312 outputs
Outputs of similar age
#11,597
of 443,777 outputs
Outputs of similar age from JAMA Oncology
#26
of 104 outputs
Altmetric has tracked 25,413,176 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 97th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 3,312 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 84.4. This one has gotten more attention than average, scoring higher than 74% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 443,777 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 97% of its contemporaries.
We're also able to compare this research output to 104 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 75% of its contemporaries.